OTL nach dem RS 1:20 WKN: A4046T ISIN: US69012T3059 Kürzel: OTLK Forum: Aktien User: Pinoy80

HEUL DOCH....😝😂

Wer heult denn ? OTLK ist bei mir noch über 75% + alles Easy 😎

Die hnen ihr komplette Geld zum shorten von micron amd und Broadcom gebraucht

Wenn ich mir die Watchlist wieder ansehe dominiert gerade ganz klar die Rote Farbe

Also wenn ich sofort erneut poste, könnte mich das System gänzlich sperren, Spamverdacht u.s.w. Ist jemand bei Reddit und könnte die neue Version bei Reddit USA posten ? : Financial Analysis on Outlook Therapeutics ($OTLK): Why Dilution Concerns Might Be Overstated : The recent market reaction surrounding Outlook Therapeutics ($OTLK) regarding the potential authorization of 340 million new shares and a Reverse Split (RS) seems exaggerated when looking closely at the actual financials and timeline.Here is a realistic breakdown of the math:The Science is Settled: The OND has granted the appeal, confirming Norse TWO and Norse EIGHT prove efficacy for LYTENAVA. The regulatory risk is drastically reduced as we head into the 60-day Class 1 Resubmission cycle.Existing Shares are Sufficient: People often overlook that management already has 43 million shares available. If the stock reaches a post-approval price between $1.00 and $2.00, utilizing these existing shares alone could generate between $43M and $86M. This is more than enough to completely fund the initial commercial rollout.Controlled Placement & Minor Dips: Instead of a massive crash, a piece-by-piece placement of these 43 million shares into a rising market would only cause a minor, healthy dip in the share price (for example, a temporary drop from $2.00 down to $1.80). This minor fluctuation is a completely normal market reaction, but it fully finances the commercial rollout without destroying shareholder value.No Immediate Need for 340M Shares: With $5M from the recent direct offering and $18.4M in unsecured credit lines, the company has enough runway to reach the finish line. Massive immediate dilution makes zero sense mathematically when the stock is at $0.80. The 340M request serves as a long-term financial safety net, not an immediate threat to shareholders.Conclusion: The current fundamentals remain very strong, and the math indicates that fears of near-term dilution are mathematically illogical.

Langsam werden Sie wach

Also wenn ich sofort erneut poste, könnte mich das System gänzlich sperren, Spamverdacht u.s.w. Ist jemand bei Reddit und könnte die neue Version bei Reddit USA posten ? : Financial Analysis on Outlook Therapeutics ($OTLK): Why Dilution Concerns Might Be Overstated : The recent market reaction surrounding Outlook Therapeutics ($OTLK) regarding the potential authorization of 340 million new shares and a Reverse Split (RS) seems exaggerated when looking closely at the actual financials and timeline.Here is a realistic breakdown of the math:The Science is Settled: The OND has granted the appeal, confirming Norse TWO and Norse EIGHT prove efficacy for LYTENAVA. The regulatory risk is drastically reduced as we head into the 60-day Class 1 Resubmission cycle.Existing Shares are Sufficient: People often overlook that management already has 43 million shares available. If the stock reaches a post-approval price between $1.00 and $2.00, utilizing these existing shares alone could generate between $43M and $86M. This is more than enough to completely fund the initial commercial rollout.Controlled Placement & Minor Dips: Instead of a massive crash, a piece-by-piece placement of these 43 million shares into a rising market would only cause a minor, healthy dip in the share price (for example, a temporary drop from $2.00 down to $1.80). This minor fluctuation is a completely normal market reaction, but it fully finances the commercial rollout without destroying shareholder value.No Immediate Need for 340M Shares: With $5M from the recent direct offering and $18.4M in unsecured credit lines, the company has enough runway to reach the finish line. Massive immediate dilution makes zero sense mathematically when the stock is at $0.80. The 340M request serves as a long-term financial safety net, not an immediate threat to shareholders.Conclusion: The current fundamentals remain very strong, and the math indicates that fears of near-term dilution are mathematically illogical.

Amis haben kein bock heute